Our facility in Horsham, Pennsylvania specializes in reproductive and developmental toxicology and features the largest group of experts and the most extensive historical control database available in the industry.

 

Areas of specialization include juvenile/pediatric studies, neurobehavioural evaluations, GLP-compliant
phototoxicology (in vitro and in vivo), safety testing of cell-based therapeutic products and studies in transgenic animals.  

 

Detailed information on our Pennsylvania site is available in The Source^SM. Click here to log in, or click here to register.  

 

Click here to contact our Pennsylvania facility.

Biomechanical strength testing of bones, considered the ultimate bone quality assessment, is a critical endpoint in the evaluation of the safety and efficacy of test compounds in neonate, juvenile, young adult and aged animals in preclinical studies. Charles River has the required experience and expertise in biomechanical testing with multiple species and ages for successful integration of these endpoints in toxicology studies. Learn more.

Charles River has validated several assays intended to analyze markers of the inflammatory response in serum and/or plasma, including acute-phase proteins such as C-reactive protein (CRP), haptoglobin and fibrinogen, as well as cytokines. Recently an in vivo study in which animals were stimulated with an anti-CD3 mAb was initiated to demonstrate the sensitivity of the validated methods, to characterize the range and dynamics of inflammatory responses after treatment, and to verify if modulation of inflammatory markers can be adequately monitored. Learn more. 

Charles River assists clients in developing cellular therapies using a strategic and consultative approach. With great consideration given to regulatory expectations and cost, our customized cellular therapy programs integrate both safety and efficacy endpoints, mitigate risk factors inherent to developing novel cellular therapies and streamline programs to reduce costs. Learn more. 

As a global research partner, we provide a full range of Drug Metabolism and Pharmacokinetics (DMPK) services associated with both drug discovery and development for both small and large molecules. 

 

We offer high-throughput in vivo drug candidate screening in support of drug registration in multiple species and can assess the absorption, distribution, metabolism and excretion (ADME) of novel therapeutic agents. These services include 

in vitro drug metabolism and metabolite identification capabilities. 

 

Below are resources available to assist you in better planning your DMPK research:

   

Drug Metabolism Datasheet

  

Poster: The Utilisation of Quantitative Whole Body Autoradiography (QWBA) Methods to Investigate Whole Body Tissue Distribution in the Minipig

 

Researcher #198 - Microautoradiography Services

   

For more information about these technologies and our DMPK capabilities, contact us at askcharlesriver@crl.com.